On Monday, June 15, 2020, the U.S. Food and Drug Administration removed the Emergency Authorization Use (EAU) of two malaria drugs to treat COVID-19, saying that they are “unlikely to be effective.”
Both hydroxychloroquine (brand name Plaquenil) and chloroquine were heavily promoted by President Trump after a handful of small, poorly controlled studies showed that they could work in treating the disease.
The FDA reported that further studies had shown that the two drugs were unlikely to be effective in stopping the virus, and that current national treatment guidelines do not recommend using them outside of clinical trials.
Hydroxychloroquine is a low-risk ototoxic drug. Please refer to this feature article for more information.
Recent Posts
Academy, ADA, and ASHA Announce the Introduction of MAAIA in the Senate
The American Academy of Audiology, Academy of Doctors of Audiology (ADA), and American Speech-Language-Hearing Association (ASHA) are pleased to announce the introduction of the Medicare…
Admission Rates of Neonatal Intensive Care Units in the United States
Pediatric audiology case-history questionnaires often ask about birth history and time spent in a neonatal intensive care unit (NICU). As such, audiologists who routinely see…
A New Flexible Auditory Brainstem Implant
An auditory brainstem implant (ABI) provides the sensation of sound to individuals who are deaf due to neurofibromatosis 2 (NF2) or a severely compromised or…